BioStem Technologies, Inc. Accounts Receivable
BioStem Technologies, Inc. (BSEM) had Accounts Receivable of $6.62 million as of 2026-06-30, per its S-1 filed 2026-09-18.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-09-18
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $6.62M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $9.87M.
- 2024-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $23.11M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $6.62M S-1 · filed 2026-09-18 |
| 2025-12-31 | $9.87M S-1 · filed 2026-09-18 |
| 2024-12-31 | $23.11M S-1 · filed 2026-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |